intraocular

(Rac)-MGV354 (MGV354) is the racemate of MGV354. MGV354 is a soluble activator of guanylate cyclase (sGC)(EC50s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively).

Taprenepag (CP-544326) (CP-544326) is a potent and selective prostaglandin E2 receptor agonist (EC50 = 2.8 nM). Taprenepag has been used in trials studying the treatment of Ocular Hypertension and Glaucoma, Open-Angle.

Timolol is a nonselective beta-adrenergic receptor blocker that is widely used for the therapy of hypertension, angina pectoris and prevention of vascular headaches.

Methazolamide (CL 8490) is a carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.

Brinzolamide (AL-4862) is a Carbonic Anhydrase Inhibitor. Its mechanism of action involves inhibiting the enzyme Carbonic Anhydrase.

DL-Adrenaline Hydrochloride is the hydrochloride salt of the naturally occurring sympathomimetic amine with vasoconstricting, intraocular pressure-reducing activities.

Aceclidine (1-azabicyclo[2.2.2]octan-3-yl acetate) is a modulator of M3 mAChR and can be used in studies about treating glaucoma by reducing intraocular pressure.

Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) is the sodium salt form of bromfenac, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory properties. Upon ophthalmic administration, bromfenac binds to and inhibits cyclooxygenase II (COX II), an enzyme that converts arachidonic acid to cyclic endoperoxides, which are prostaglandin (PG) precursors. By inhibiting PG formation, bromfenac prevents PG-induced inflammation, vasodilation, leukocytosis, disruption of the blood-aqueous humor barrier, increased vascular permeability, and elevated intraocular pressure (IOP).

Brimonidine Tartrate (AGN190342 tartrate) is a quinoxaline derivative and adrenergic α-2 receptor agonist (EC50: 0.45 nM) that is used to manage intraocular pressure associated with open-angle glaucoma or ocular hypertension.

IMS2186 is a reagent with activity of antichoroidal neovascularization (CNV). IMS2186 could arrest cancer cell cycle in G2 M phase, result in exerting anti-proliferation and anti-angiogenesis effects. IMS2186 reduces the amount of eye leakage and diseased cells with no intraocular toxicity.

AR-13324 analog mesylate, an inhibitor of Rho-kinase and the norepinephrine transporter, reduces intraocular pressure in normotensive monkey eyes.

Netarsudil Dihydrochloride (AR-13324 Dihydrochloride) is an inhibitor of Rho-related protein kinase (ROCK) and norepinephrine transporter (NET) and is effective in reducing intraocular pressure (IOP).

Latanoprost lactone diol is an important intermediate compound in the synthesis of Latanoprost. Latanoprost, classified as a prostaglandin F2α analogue, functions as an agonist for the FP prostanoid receptor, resulting in a reduction in intraocular pressure (IOP).

Y-33075 (Y-39983 free base) is a ROCK inhibitor that lowers intraocular pressure (IOP), increases blood flow to the optic nerve head (ONH), and increases the number of RGCs (retinal ganglion cells) in the body with regenerating axons.

Unoprostone is a prostaglandin F2α analogs (PGAs), and reduces intraocular pressure and is used topically for glaucoma or ocular hypertension.

Latanoprostene bunod (LBN) is nitric oxide (NO)-donating prostaglandin F2a analog and is a topical ophthalmic therapeutic. It is used for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (OHT).

Tetrahydrocortisol (Tetrahydrohydrocortisone) is a metabolite of neurosteroids and cortisol, a GABAA receptor antagonist, and also capable of lowering intraocular pressure.

Levobetaxolol, also known as AL-1577A and Betaxon, is a cardioselective β-adrenergic receptor inhibitor. It has been demonstrated to reduce intraocular pressure in patients affected by ocular hypertension and primary open-angle glaucoma.

ent-Levobunolol (hydrochloride) ((R)-Bunolol (hydrochloride)) is a competitive β-adrenergic receptor blocker. It functions by inhibiting the transmission of sympathetic nerve impulses, reducing the production of aqueous humor, and constricting blood vessels within the eye, thereby lowering intraocular pressure. This compound shows potential for research in conditions like glaucoma and other ocular hypertension disorders.

AL-34662 (formate) is a 5-HT2 receptor agonist with an IC50 of 0.8-1.5 nM. It stimulates phosphoinositol turnover and Ca2+ release in human ciliary muscle cells (h-CM) with an E50 of 289 nM and in human trabecular meshwork cells (h-TM) with an E50 of 254 nM. It is used in research on reducing intraocular pressure (IOP).

Apraclonidine hydrochloride (ALO 2145) is an α2-adrenergic agonist and a weak α-1 adrenergic receptor agonist. Apraclonidine hydrochloride lowers intraocular pressure in human eyes and can be used in studies about glaucoma therapy.

AL 34662 is a selective and potent 5-HT2A receptor agonist with IC50s of 0.77 nM and 1.5 nM for rat and human 5-HT2 receptors, respectively.AL 34662 is also a low affinity α-1D adrenergic agonist, with an EC50 of 0.4 μM.AL 34662 can be used to lower intraocular pressure.

H-0104 Dihydrochloride is an inhibitor of ROCK that acts by applying potent intraocular pressure (IOP)-lowering effects into the eyes of monkeys.

H-0106 Dihydrochloride is an inhibitor of ROCK that acts by applying strong intraocular pressure (IOP)-lowering effects into the eyes of monkeys.